Total Payments
$70,768
2023 Payments
$9,969
Companies
9
Transactions
64
Medicare Patients
1,406
Medicare Billing
$232,302
Payment Breakdown by Category
Other$41,594 (58.8%)
Consulting$23,542 (33.3%)
Travel$3,997 (5.6%)
Food & Beverage$1,529 (2.2%)
Education$105.97 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $41,594 | 12 | 58.8% |
| Consulting Fee | $23,542 | 11 | 33.3% |
| Travel and Lodging | $3,997 | 16 | 5.6% |
| Food and Beverage | $1,529 | 22 | 2.2% |
| Education | $105.97 | 3 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Horizon Therapeutics plc | $28,696 | 24 | $0 (2023) |
| Alnylam Pharmaceuticals Inc. | $11,125 | 2 | $0 (2022) |
| Horizon Pharma plc | $10,326 | 4 | $0 (2018) |
| Relypsa, Inc. | $8,373 | 15 | $0 (2018) |
| Exeltis, USA Inc. | $7,150 | 13 | $0 (2022) |
| Amgen Inc. | $3,285 | 2 | $0 (2023) |
| Keryx Biopharmaceuticals, Inc. | $1,202 | 2 | $0 (2018) |
| GlaxoSmithKline, LLC. | $500.00 | 1 | $0 (2017) |
| Bayer HealthCare Pharmaceuticals Inc. | $111.40 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $9,969 | 12 | Horizon Therapeutics plc ($6,684) |
| 2022 | $22,666 | 20 | Alnylam Pharmaceuticals Inc. ($8,900) |
| 2021 | $7,316 | 4 | Horizon Therapeutics plc ($4,980) |
| 2019 | $10,416 | 6 | Horizon Therapeutics plc ($10,416) |
| 2018 | $14,349 | 12 | Horizon Pharma plc ($8,976) |
| 2017 | $6,051 | 10 | Relypsa, Inc. ($4,201) |
All Payment Transactions
64 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2023 | Amgen Inc. | TAVNEOS (Drug) | Consulting Fee | Cash or cash equivalent | $1,971.00 | General |
| Category: Inflammation | ||||||
| 11/04/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Honoraria | Cash or cash equivalent | $1,750.00 | General |
| Category: KRYSTEXXA | ||||||
| 11/04/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Honoraria | Cash or cash equivalent | $1,750.00 | General |
| Category: KRYSTEXXA | ||||||
| 11/04/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $124.25 | General |
| Category: KRYSTEXXA | ||||||
| 11/04/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $32.13 | General |
| Category: KRYSTEXXA | ||||||
| 10/06/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Honoraria | Cash or cash equivalent | $2,739.00 | General |
| Category: KRYSTEXXA | ||||||
| 10/06/2023 | Amgen Inc. | TAVNEOS (Drug) | Consulting Fee | Cash or cash equivalent | $1,314.00 | General |
| Category: Inflammation | ||||||
| 10/06/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | Cash or cash equivalent | $84.84 | General |
| Category: KRYSTEXXA | ||||||
| 10/06/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | Cash or cash equivalent | $64.65 | General |
| Category: KRYSTEXXA | ||||||
| 10/06/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Education | Cash or cash equivalent | $57.50 | General |
| Category: KRYSTEXXA | ||||||
| 10/06/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Education | Cash or cash equivalent | $46.70 | General |
| Category: KRYSTEXXA | ||||||
| 10/06/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | Cash or cash equivalent | $34.90 | General |
| Category: KRYSTEXXA | ||||||
| 12/08/2022 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $8,900.00 | General |
| 11/04/2022 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $34.80 | General |
| Category: KRYSTEXXA | ||||||
| 05/21/2022 | Exeltis, USA Inc. | PURIFIED CORTROPHIN GEL (Drug) | Honoraria | Cash or cash equivalent | $5,462.50 | General |
| Category: Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA | ||||||
| 05/21/2022 | Exeltis, USA Inc. | PURIFIED CORTROPHIN GEL (Drug) | Travel and Lodging | In-kind items and services | $737.20 | General |
| Category: Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA | ||||||
| 05/21/2022 | Exeltis, USA Inc. | PURIFIED CORTROPHIN GEL (Drug) | Travel and Lodging | In-kind items and services | $231.85 | General |
| Category: Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA | ||||||
| 05/21/2022 | Exeltis, USA Inc. | PURIFIED CORTROPHIN GEL (Drug) | Travel and Lodging | In-kind items and services | $230.52 | General |
| Category: Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA | ||||||
| 05/21/2022 | Exeltis, USA Inc. | PURIFIED CORTROPHIN GEL (Drug) | Travel and Lodging | In-kind items and services | $197.86 | General |
| Category: Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA | ||||||
| 05/21/2022 | Exeltis, USA Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA | ||||||
| 05/21/2022 | Exeltis, USA Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA | ||||||
| 05/21/2022 | Exeltis, USA Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $34.99 | General |
| Category: Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA | ||||||
| 05/21/2022 | Exeltis, USA Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $34.99 | General |
| Category: Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA | ||||||
| 05/21/2022 | Exeltis, USA Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $29.99 | General |
| Category: Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA | ||||||
| 05/21/2022 | Exeltis, USA Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $29.99 | General |
| Category: Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 358 | 638 | $285,453 | $61,293 |
| 2022 | 6 | 329 | 679 | $276,407 | $57,582 |
| 2021 | 7 | 317 | 646 | $255,561 | $55,676 |
| 2020 | 9 | 402 | 706 | $263,698 | $57,751 |
Total Patients
1,406
Total Services
2,669
Medicare Billing
$232,302
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 107 | 295 | $122,720 | $29,300 | 23.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 51 | 87 | $52,113 | $10,431 | 20.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 82 | 121 | $48,853 | $9,025 | 18.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 54 | 55 | $30,189 | $6,055 | 20.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 31 | 41 | $11,890 | $2,747 | 23.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 16 | 16 | $12,880 | $2,349 | 18.2% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 17 | 23 | $6,808 | $1,387 | 20.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 110 | 300 | $123,117 | $26,274 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 95 | 192 | $76,375 | $15,112 | 19.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 68 | 71 | $38,321 | $8,214 | 21.4% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 20 | 55 | $16,240 | $3,401 | 20.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 24 | 45 | $12,994 | $2,725 | 21.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 12 | 16 | $9,360 | $1,856 | 19.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 99 | 264 | $111,552 | $23,599 | 21.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 82 | 204 | $69,980 | $16,718 | 23.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 68 | 69 | $38,553 | $7,881 | 20.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 30 | 57 | $16,779 | $3,325 | 19.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 15 | 15 | $7,985 | $1,737 | 21.7% |
| 90945 | Dialysis procedure including one evaluation | Facility | 2021 | 11 | 20 | $7,100 | $1,518 | 21.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 12 | 17 | $3,612 | $898.03 | 24.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 108 | 253 | $105,095 | $23,254 | 22.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 67 | 126 | $39,977 | $8,314 | 20.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 70 | 129 | $37,567 | $8,257 | 22.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 65 | 66 | $36,144 | $8,051 | 22.3% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2020 | 33 | 68 | $19,863 | $4,389 | 22.1% |
About Dr. David Mount, MD
Dr. David Mount, MD is a Nephrology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1225076771.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Mount, MD has received a total of $70,768 in payments from pharmaceutical and medical device companies, with $9,969 received in 2023. These payments were reported across 64 transactions from 9 companies. The most common payment nature is "Honoraria" ($41,594).
As a Medicare-enrolled provider, Mount has provided services to 1,406 Medicare beneficiaries, totaling 2,669 services with total Medicare billing of $232,302. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Boston, MA
- Active Since 06/04/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1225076771
Products in Payments
- KRYSTEXXA (Biological) $28,696
- KRYSTEXXA (Drug) $10,326
- Veltassa (Drug) $8,373
- PURIFIED CORTROPHIN GEL (Drug) $7,150
- TAVNEOS (Drug) $3,285
- Auryxia (Drug) $1,202
- Kerendia (Drug) $111.40
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Boston
David Friedman, M.d, M.D
Nephrology — Payments: $20.3M
Nephrology $20.3M
Martin Pollak, Md, MD
Nephrology — Payments: $20.3M
Nephrology $20.3M
Dr. Dennis Ausiello, Md, MD
Nephrology — Payments: $4.4M
Nephrology $4.4M
Dr. Ajay Singh, Md, MD
Nephrology — Payments: $1.2M
Nephrology $1.2M
Dr. Leslie Fang, Md, MD
Nephrology — Payments: $795,357
Nephrology $795,357
Dr. Jean Francis, M.d, M.D
Nephrology — Payments: $217,413
Nephrology $217,413